CORONA Remedies Limited (CORONA) receives ANVISA GMP certification for Bhayla manufacturing, reinforcing its commitment to 'One World, One Quality'.
CORONA Remedies Limited (CORONA) reports Q1 FY27 revenue and PAT growth of 21.9% and 30.1% Y-o-Y, driven by brand building and operational excellence.
CORONA Remedies Limited commercialises India's most advanced EU-GMP approved women's hormone manufacturing facility, marking a significant milestone in women.
CORONA Remedies Limited (CORONA) secures EU-GMP accreditation for its Hormone and Oral Solid Dosage facilities, boosting its global market expansion.